Business Description
Rain Oncology Inc
NAICS : 541714
SIC : 2834
ISIN : US75082Q1058
Description
Rain Oncology Inc is a late-stage precision oncology company developing therapies that target oncogenic drivers for which it is able to genetically select patients it believes will likely benefit. This approach includes using a tumor-agnostic approach to select patients based on their tumors' underlying genetics rather than histology. The company's product candidate, milademetan, is a small molecule, oral inhibitor of MDM2, which is oncogenic in numerous cancers. In addition to milademetan, the company is also developing a preclinical program that is focused on inducing synthetic lethality in cancer cells by inhibiting RAD52.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 169.56 | |||||
| Equity-to-Asset | 0.82 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | -0.01 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -39.4 | |||||
| 3-Year EPS without NRI Growth Rate | -38.4 | |||||
| 3-Year FCF Growth Rate | -28.6 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 40.97 | |||||
| 9-Day RSI | 49.34 | |||||
| 14-Day RSI | 53.89 | |||||
| 6-1 Month Momentum % | -11.03 | |||||
| 12-1 Month Momentum % | -87.9 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 5.58 | |||||
| Quick Ratio | 5.58 | |||||
| Cash Ratio | 5.34 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -50.4 | |||||
| Shareholder Yield % | -0.62 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -84.06 | |||||
| ROA % | -69.78 | |||||
| ROIC % | -2700.4 | |||||
| ROC (Joel Greenblatt) % | -13877.35 | |||||
| ROCE % | -85.68 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 0.65 | |||||
| Price-to-Tangible-Book | 0.65 | |||||
| EV-to-EBIT | 0.45 | |||||
| EV-to-Forward-EBIT | -4.46 | |||||
| EV-to-EBITDA | 0.45 | |||||
| EV-to-FCF | 0.5 | |||||
| Price-to-Net-Current-Asset-Value | 0.66 | |||||
| Price-to-Net-Cash | 0.7 | |||||
| Earnings Yield (Greenblatt) % | 222.22 | |||||
| FCF Yield % | -149.39 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers